Elutia Inc. (NASDAQ: ELUT) had its price target raised by analysts at Lake Street Capital from $5.00 to $10.00. They now have a "buy" rating on the stock.
Elutia, Inc. - Class A (ELUT)
Company Research
Source: MarketBeat
Impact Snapshot
Event Time:
ELUT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ELUT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ELUT alerts
High impacting Elutia, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
ELUT
News
- Elutia Inc. (NASDAQ: ELUT) had its price target raised by analysts at Cantor Fitzgerald from $5.00 to $11.00. They now have an "overweight" rating on the stock.MarketBeat
- Elutia Announces $13.26 Million Registered Direct OfferingGlobeNewswire
- Elutia Announces FDA Clearance of EluPro®: The First Antibiotic-Eluting BioEnvelope Designed to Protect Patients with Implantable Cardiac Pacemakers and DefibrillatorsGlobeNewswire
- Elutia to Showcase BioEnvelope Product Line at Heart Rhythm 2024GlobeNewswire
- Elutia Inc. (NASDAQ: ELUT) had its price target lowered by analysts at Cantor Fitzgerald from $6.00 to $5.00. They now have an "overweight" rating on the stock.MarketBeat